Use of an auditor that cannot be inspected by the US regulator takes centre stage as Chinese biotech stocks fall.
At a meeting lacking practice-changing studies and featuring many disappointments the downturn in IGM’s fortunes stands out.
Novartis unveils the first clinical backing for a two-day manufacturing technique that it hopes will recharge its Car-T efforts.
Whether investor enthusiasm for drug stocks holds up this year is the burning question for IPO followers.
With many of the usual targets on display Fate, Celyad, Allovir and others look to maintain momentum.
The Chinese group sees responses in all five subjects treated with its allogeneic anti-CD7 Car-T therapy.
Next week’s virtual meeting could resuscitate Ox40 agonists, but an important omission will disappoint.